You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, September 2021
|
| DOI | 10.1186/s13023-021-01876-4 |
| Pubmed ID | |
| Authors |
Bob Stevens, Tom Kenny, Sophie Thomas, Alexandra Morrison, James Jarrett, Mohit Jain |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 60% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 7 | 17% |
| Student > Ph. D. Student | 5 | 12% |
| Student > Bachelor | 4 | 10% |
| Student > Doctoral Student | 3 | 7% |
| Researcher | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 16 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 7 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Nursing and Health Professions | 2 | 5% |
| Psychology | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 16 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2021.
All research outputs
#6,503,697
of 23,310,485 outputs
Outputs from Orphanet Journal of Rare Diseases
#896
of 2,673 outputs
Outputs of similar age
#129,418
of 433,130 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#26
of 112 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,673 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 433,130 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 112 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.